The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

New research, with the caveat of a relatively short follow-up, adds to encouraging data showing an overall low risk of the development of thyroid cancer associated with glucagon-like peptide 1 ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

the use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs shows no significantly increased risk for thyroid cancer, with the important caveat of the study’s relatively short follow-up ...

A recent JAMA Otolaryngology-Head & Neck Surgery study investigates the risk of incident thyroid cancer among adults diagnosed with type 2 diabetes (T2D) and being treated with either glucagon ...

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary analysis of a target trial emulation of a comparative effectiveness study found.

The risk for thyroid cancer within the first year of follow-up was higher with GLP-1 therapy vs. other diabetes drugs. Researchers attributed the higher thyroid cancer risk with GLP-1s to ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in Thyroid.